跳到主要导航 跳到搜索 跳到主要内容

Development and validation of a prognostic staging system for primary plasma cell leukemia

  • Mengru Tian
  • , Gang An
  • , Weijun Fu
  • , Wenqiang Yan
  • , Lu Li
  • , Chunyan Sun
  • , Zhenyu Li
  • , Lijuan Chen
  • , Aijun Liao
  • , Guangxun Gao
  • , Xiaoqi Qin
  • , Mengyao Li
  • , Chunrui Li
  • , Hua Xue
  • , Li Gao
  • , Yi Wang
  • , Aili He
  • , Fan Zhou
  • , Dongmei Guo
  • , Yujun Dong
  • Zhihong Fang, Xiaoxia Chu, Jianqing Mi, Chengcheng Fu, Hui Zeng, Shuling Hou, Xiaotao Wang, Hua Wang, Yongqiang Wei, Xinyue Liang, Xingcheng Yi, Yue Sun, Lugui Qiu, Yun Dai, Fengyan Jin
  • Jilin University
  • Chinese Academy of Medical Sciences
  • Tianjin Institutes of Health Science
  • Tongji University
  • Huazhong University of Science and Technology
  • Xuzhou Medical University
  • The First Affiliated Hospital with Nanjing Medical University
  • China Medical University
  • Air Force Medical University
  • Shanxi Medical University
  • Hebei University
  • Army Medical University
  • Shaanxi Provincial People’s Hospital
  • The Second Affiliated Hospital of Xi'an Jiaotong University
  • Shanghai Jing’an District Zhabei Central Hospital
  • Qilu Hospital of Shandong University (Qingdao)
  • Peking University
  • The First Affiliated Hospital of Xiamen University
  • Yantai Yuhuangding Hospital
  • Shanghai Jiao Tong University
  • The First Affiliated Hospital of Soochow University
  • Guangdong Academy of Medical Sciences
  • Shanxi Bethune Hospital
  • Guilin Medical College
  • Sun Yat-Sen University Cancer Center
  • Southern Medical University

科研成果: 期刊稿件文章同行评审

4 引用 (Scopus)

摘要

Background: The existing risk models for multiple myeloma (MM) are suboptimal for the stratification of patients with primary plasma cell leukemia (pPCL), a rare and peculiar MM. In this study, we aimed to develop a staging system for pPCL defined as the presence of ≥ 5% circulating plasma cells (CPC) according to the new diagnostic criteria, utilizing one of the largest series of patients with pPCL. Methods: This multicenter retrospective study included 340 patients with pPCL (the training cohort) from 25 centers nationwide in China. The prognostic impact of baseline characteristics and cytogenetic abnormalities was evaluated. Univariate and multivariate analyses were conducted to identify variables predicting overall survival (OS) to develop a staging system. Its performance was then validated in an independent cohort (n = 80). Genome-wide DNA and RNA sequencing were performed to explore the molecular basis for inter-stage clinical heterogeneity. Results: Del(17p), t(4;14), and t(14;16), but not 1q+, were verified as high-risk cytogenetic abnormalities (HRCAs) of pPCL. HRCA, elevated LDH, and thrombocytopenia had the highest impact on OS and were used to create a simple algorithm, stratifying patients with pPCL into stages I, II, and III, with median OS of 54.1, 24.0, and 5.4 months (II vs. I: HR, 1.986; 95% CI, 1.034–3.814; P = 0.0394; III vs. II: HR, 3.206; 95% CI, 1.757–5.852; P = 0.0001) in the training cohort and 62.1, 31.6, and 21.8 months (II vs. I: HR, 2.013; 95% CI, 0.954–4.251; P = 0.0664; III vs. II: HR, 2.694; 95% CI, 1.136–6.392; P = 0.0245) in the independent validation cohort. The accuracy (c-index 0.711) was higher than other models. Moreover, patients with different stages had highly diverse genomic and transcriptomic aberrations. Conclusions: We propose a pPCL-specific staging system based on LDH, thrombocytopenia, and cytogenetic abnormalities, which warrants further validation, particularly in a prospective setting.

源语言英语
文章编号72
期刊Journal of Hematology and Oncology
18
1
DOI
出版状态已出版 - 12月 2025
已对外发布

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

学术指纹

探究 'Development and validation of a prognostic staging system for primary plasma cell leukemia' 的科研主题。它们共同构成独一无二的指纹。

引用此